A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges

Figure 1

Schematic representation of human FGFR3 protein and corresponding FGFR3 coding exons. Exon numbering based on Tomlinson et al. [38]. Type and total number of reported mutations are based on data pooled from 11 studies [25–29, 31, 32, 39–42], including a total of 1898 bladder tumours. SP: signal peptide; IgI–III: immunoglobulin-like domain; AB: acid box; TM: transmembrane domain; TK; tyrosine-kinase domain.